Tagged with Strategy

USA Indian firm Biocon has seen great success in the US in recent years, with two biosimilar launches and a range of generic medicines now available on the American market.   In a recent interview with PharmaBoardroom, Biocon’s Commercial Head Global Generics & SVP Marketing Abhijit Zutshi outlined the company’s recipe…

Morocco Salim El Guermai, CEO & head pharmacist of Galenica, a leading generics company in Morocco, presents the original mission of the company to provide high-quality affordable medicines to Moroccan patients by developing and manufacturing its own portfolio as an alternative to expensive imported drugs. El Guermai also shares his ambitions…

Mexico Americo Garcia oversees Latin American operations for Canadian generics player Apotex. He outlines the firm’s impressive growth in the region in recent years – expanding both in terms of portfolio and geographies -, gives his take on the proposed Mexican healthcare reforms, and explains how he has been able to…

Belgium Ian Wilders of Spain-headquartered micro-immunotherapy specialist Labo’Life discusses the strategic importance of Belgium to the company as the country in which micro-immunotherapy was discovered and where regulation conducive to the introduction of these therapies is increasingly being introduced.   Micro-immunotherapy was the discovery of a Belgian doctor therefore it is…

USA Abhijit Zutshi, commercial head global generics & SVP marketing at Indian firm Biocon highlights the challenges inherent in the US generics market, the process of setting up an affiliate in the US, and how Biocon’s level of vertical integration allows it to be highly competitive and stand out from the…

Morocco Ali Besri, Pfizer Morocco GM and North Africa Lead reveals the importance of Morocco’s stability and assets allowing the country to be recognized internationally for its manufacturing investments and capabilities and highlights how Pfizer has capitalized on this with a footprint in the country for over half a century. Looking…

Belgium Anne-Laure Dreno, country president of AstraZeneca in Belgium, elaborates on the significant position Belgium and the local affiliate have for the group as a frontrunner in innovative areas such as creating value-based agreements for reimbursements, (clinical) research and development, and embracing the opportunities of patient data. Dreno also discusses her…

Janssen Myriem Tamimy gives an overview of the ongoing situation for Janssen and pharma multinationals more generally in Morocco, discusses the next steps in the authorities’ pharma strategy and the role that multinationals will have in the process, and highlights the challenges related to managing in a time of COVID-19.  …

UAE Ousama Al Haj, director for UAE, Bahrain, Oman & Qatar at AstraZeneca, highlights the company’s substantial growth and favourable position in the Gulf markets, explains how the company is overcoming the local healthcare dynamics by partnering with local authorities to offer patients’ platforms instead of products, and analyzes AstraZeneca’s future…

China PharmaBoardroom caught up with Dr Jingsong Wang, chairman & CEO of Harbour BioMed to discuss the exciting clinical and commercial milestones of the prolific biotech in the last year since we last met them in January 2019, including their March USD 75 million Series B+ fundraising round and their preparations…

Opinion John G. Singer examines how the ongoing coronavirus pandemic may create a new dichotomy for global healthcare – and why pharma companies still wedded to the market models of the past risk getting left behind.   “Drug” companies have a unique opportunity to invent a different market for themselves. It…

Belgium Brigitte Nolet, country manager of Roche for Belgium and Luxembourg, speaks about her transition to the Belgian market and her priorities for leading the affiliate. Nolet goes on the elaborate on the vast commitment Roche has to the Belgian market and the company’s mission not only to drive innovation but…